{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:14:34Z","timestamp":1787026474072,"version":"build-2736575974"},"reference-count":45,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,6,5]],"date-time":"2020-06-05T00:00:00Z","timestamp":1591315200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100008478","name":"Instituto Nacional del C\u00e1ncer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008478","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"DOI":"10.3389\/fimmu.2020.01147","type":"journal-article","created":{"date-parts":[[2020,6,5]],"date-time":"2020-06-05T00:51:56Z","timestamp":1591318316000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":22,"title":["Evaluation of T-Cell Responses Against Shared Melanoma Associated Antigens and Predicted Neoantigens in Cutaneous Melanoma Patients Treated With the CSF-470 Allogeneic Cell Vaccine Plus BCG and GM-CSF"],"prefix":"10.3389","volume":"11","author":[{"given":"Enrique","family":"Podaza","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ibel","family":"Carri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariana","family":"Aris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erika","family":"von Euw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alicia In\u00e9s","family":"Bravo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula","family":"Blanco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Manuel","family":"Ortiz Wilczy\u00f1ski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Koile","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricio","family":"Yankilevich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morten","family":"Nielsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9","family":"Mordoh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Marcela","family":"Barrio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2020,6,5]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined Nivolumab and Ipilimumab or monotherapy in untreated melanoma","volume":"373","author":"Larkin","year":"2015","journal-title":"N Engl J Med."},{"key":"B2","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/S0140-6736(16)32517-X","article-title":"Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial","volume":"389","author":"Rittmeyer","year":"2017","journal-title":"Lancet."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1056\/NEJMoa1910836","article-title":"Five-year survival with combined nivolumab and ipilimumab in advanced melanoma","volume":"381","author":"Larkin","year":"2019","journal-title":"N Engl J Med."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1056\/NEJMoa1802357","article-title":"Adjuvant Pembrolizumab versus placebo in resected stage III melanoma","volume":"378","author":"Eggermont","year":"2018","journal-title":"N Engl J Med."},{"key":"B5","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.semcancer.2019.08.024","article-title":"The adjuvant treatment revolution for high-risk melanoma patients","volume":"59","author":"Spagnolo","year":"2019","journal-title":"Semin Cancer Biol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1038\/nature13954","article-title":"PD-1 blockade induces responses by inhibiting adaptive immune resistance","volume":"515","author":"Tumeh","year":"2014","journal-title":"Nature."},{"key":"B7","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1186\/1479-5876-11-89","article-title":"Sequencing CTLA-4 blockade with cell-based immunotherapy for prostate cancer","volume":"11","author":"Wada","year":"2013","journal-title":"J Transl Med."},{"key":"B8","doi-asserted-by":"publisher","first-page":"8121985","DOI":"10.1155\/2016\/8121985","article-title":"Adjuvant autologous melanoma vaccine for macroscopic stage III disease: survival, biomarkers, and improved response to CTLA-4 blockade","volume":"2016","author":"Lotem","year":"2016","journal-title":"J Immunol Res."},{"key":"B9","doi-asserted-by":"publisher","first-page":"625","DOI":"10.3389\/fimmu.2017.00625","article-title":"Phase II study of adjuvant immunotherapy with the CSF-470 vaccine plus bacillus calmette-guerin plus recombinant human granulocyte macrophage-colony stimulating factor vs medium-dose interferon alpha 2B in stages IIB, IIC, and III cutaneous melanoma patients: a single institution, randomized study","volume":"8","author":"Mordoh","year":"2017","journal-title":"Front Immunol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"955","DOI":"10.3389\/fimmu.2018.00955","article-title":"Changes in the TCR\u03b2 repertoire and tumor immune signature from a cutaneous melanoma patient immunized with the CSF-470 vaccine: a case report","volume":"9","author":"Aris","year":"2018","journal-title":"Front Immunol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"2213","DOI":"10.3389\/fimmu.2019.02213","article-title":"Immunization with the CSF-470 vaccine plus BCG and rhGM-CSF induced in a cutaneous melanoma patient a TCR\u03b2 repertoire found at vaccination site and tumor infiltrating lymphocytes that persisted in blood","volume":"10","author":"Aris","year":"2019","journal-title":"Front Immunol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.3389\/fimmu.2018.02531","article-title":"Dissecting the immune stimulation promoted by CSF-470 vaccine plus adjuvants in cutaneous melanoma patients: long term antitumor immunity and short term release of acute inflammatory reactants","volume":"9","author":"Pampena","year":"2018","journal-title":"Front Immunol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1146\/annurev.immunol.021908.132612","article-title":"Immunological and inflammatory functions of the interleukin-1 family","volume":"27","author":"Dinarello","year":"2009","journal-title":"Annu Rev Immunol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"144","DOI":"10.3389\/fimmu.2015.00144","article-title":"Inoculation site from a cutaneous melanoma patient treated with an allogeneic therapeutic vaccine: a case report","volume":"6","author":"Aris","year":"2015","journal-title":"Front Immunol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1007\/s00262-015-1743-z","article-title":"Cytokine-enhanced maturation and migration to the lymph nodes of a human dying melanoma cell-loaded dendritic cell vaccine","volume":"64","author":"Pizzurro","year":"2015","journal-title":"Cancer Immunol Immunother."},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2007.06.033","article-title":"Vaccine therapy for melanoma: current status and future directions","volume":"25","author":"Terando","year":"2007","journal-title":"Vaccine."},{"key":"B17","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1016\/j.humimm.2015.05.001","article-title":"An integrated genotyping approach for HLA and other complex genetic systems","volume":"76","author":"Nelson","year":"2015","journal-title":"Hum Immunol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1007\/s00262-017-1978-y","article-title":"TANTIGEN: a comprehensive database of tumor T cell antigens","volume":"66","author":"Olsen","year":"2017","journal-title":"Cancer Immunol Immunother."},{"key":"B19","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1038\/nbt.2514","article-title":"Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples","volume":"31","author":"Cibulskis","year":"2013","journal-title":"Nat Biotechnol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"D777","DOI":"10.1093\/nar\/gkw1121","article-title":"COSMIC: somatic cancer genetics at high-resolution","volume":"45","author":"Forbes","year":"2017","journal-title":"Nucleic Acids Res."},{"key":"B21","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1093\/nar\/29.1.308","article-title":"dbSNP: the NCBI database of genetic variation","volume":"29","author":"Sherry","year":"2001","journal-title":"Nucleic Acids Res."},{"key":"B22","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1186\/s13059-016-0974-4","article-title":"The ensembl variant effect predictor","volume":"17","author":"McLaren","year":"2016","journal-title":"Genome Biol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1007\/s00262-017-2001-3","article-title":"MuPeXI: prediction of neo-epitopes from tumor sequencing data","volume":"66","author":"Bjerregaard","year":"2017","journal-title":"Cancer Immunol Immunother."},{"key":"B24","doi-asserted-by":"publisher","first-page":"3360","DOI":"10.4049\/jimmunol.1700893","article-title":"NetMHCpan-4.0: Improved Peptide-MHC class I interaction predictions integrating eluted ligand and peptide binding affinity data","volume":"199","author":"Jurtz","year":"2017","journal-title":"J Immunol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1111\/imm.12889","article-title":"Improved methods for predicting peptide binding affinity to MHC class II molecules","volume":"154","author":"Jensen","year":"2018","journal-title":"Immunology."},{"key":"B26","doi-asserted-by":"publisher","first-page":"16168","DOI":"10.1073\/pnas.242600099","article-title":"Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells","volume":"99","author":"Yee","year":"2002","journal-title":"Proc Natl Acad Sci USA."},{"key":"B27","doi-asserted-by":"publisher","first-page":"2913","DOI":"10.1200\/JCO.1998.16.9.2913","article-title":"Correlation of specific immune responses with survival in melanoma patients with distant metastases receiving polyvalent melanoma cell vaccine","volume":"16","author":"Hsueh","year":"1998","journal-title":"J Clin Oncol."},{"key":"B28","first-page":"1347","article-title":"Delayed-type hypersensitivity response is a predictor of peripheral blood T-cell immunity after HER-2\/neu peptide immunization","volume":"6","author":"Disis","year":"2000","journal-title":"Clin Cancer Res."},{"key":"B29","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1111\/imm.12803","article-title":"Tools to define the melanoma-associated immunopeptidome","volume":"152","author":"Braunlein","year":"2017","journal-title":"Immunology."},{"key":"B30","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1038\/nature06309","article-title":"Adaptive immunity maintains occult cancer in an equilibrium state","volume":"450","author":"Koebel","year":"2007","journal-title":"Nature."},{"key":"B31","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1097\/CAD.0000000000000526","article-title":"Spontaneous regression of malignant melanoma - is it based on the interplay between host immune system and melanoma antigens?","volume":"28","author":"Cervinkova","year":"2017","journal-title":"Anti Cancer Drugs."},{"key":"B32","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/j.coi.2013.03.005","article-title":"Human cancer regression antigens","volume":"25","author":"Kvistborg","year":"2013","journal-title":"Curr Opin Immunol."},{"key":"B33","first-page":"3697","article-title":"Melanocyte-specific immune response in a patient with multiple regressing nevi and a history of melanoma","volume":"31","author":"Speeckaert","year":"2011","journal-title":"Anticancer Res."},{"key":"B34","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1200\/JCO.2010.32.2537","article-title":"Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1","volume":"29","author":"Robbins","year":"2011","journal-title":"J Clin Oncol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1007\/s00262-018-02292-7","article-title":"Natural T cell autoreactivity to melanoma antigens: clonally expanded melanoma-antigen specific CD8 + memory T cells can be detected in healthy humans","volume":"68","author":"Przybyla","year":"2019","journal-title":"Cancer Immunol Immunother."},{"key":"B36","doi-asserted-by":"publisher","first-page":"2515135519862234","DOI":"10.1177\/2515135519862234","article-title":"Therapeutic vaccination immunomodulation: forming the basis of all cancer immunotherapy","volume":"7","author":"Coventry","year":"2019","journal-title":"Ther Adv Vaccines Immunother."},{"key":"B37","doi-asserted-by":"publisher","first-page":"5954","DOI":"10.4049\/jimmunol.168.11.5954","article-title":"Characterization of CD4(+) CTLs ex vivo","volume":"168","author":"Appay","year":"2002","journal-title":"J Immunol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"8368","DOI":"10.1158\/0008-5472.CAN-10-1322","article-title":"CD4+ T-cell help in the tumor milieu is required for recruitment and cytolytic function of CD8+ T lymphocytes","volume":"70","author":"Bos","year":"2010","journal-title":"Cancer Res."},{"key":"B39","doi-asserted-by":"publisher","first-page":"6047","DOI":"10.4049\/jimmunol.165.11.6047","article-title":"Tumor-specific CD4+ T cells have a major post-licensing role in CTL mediated anti-tumor immunity","volume":"165","author":"Marzo","year":"2000","journal-title":"J Immunol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1038\/nm1554","article-title":"IFN-gamma mediates CD4+ T-cell loss and impairs secondary antitumor responses after successful initial immunotherapy","volume":"13","author":"Berner","year":"2007","journal-title":"Nat Med."},{"key":"B41","doi-asserted-by":"publisher","first-page":"2698","DOI":"10.1056\/NEJMoa0800251","article-title":"Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1","volume":"358","author":"Hunder","year":"2008","journal-title":"N Engl J Med."},{"key":"B42","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1038\/nrurol.2014.15","article-title":"The mechanism of action of BCG therapy for bladder cancer\u2013a current perspective","volume":"11","author":"Redelman-Sidi","year":"2014","journal-title":"Nat Rev Urol."},{"key":"B43","doi-asserted-by":"publisher","first-page":"174","DOI":"10.3389\/fimmu.2014.00174","article-title":"How do CD4(+) T cells detect and eliminate tumor cells that either lack or express MHC class II molecules?","volume":"5","author":"Haabeth","year":"2014","journal-title":"Front Immunol."},{"key":"B44","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1038\/nature14001","article-title":"Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing","volume":"515","author":"Yadav","year":"2014","journal-title":"Nature."},{"key":"B45","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1038\/nature23003","article-title":"Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer","volume":"547","author":"Sahin","year":"2017","journal-title":"Nature."}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2020.01147\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,5]],"date-time":"2020-06-05T00:52:01Z","timestamp":1591318321000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2020.01147\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,5]]},"references-count":45,"alternative-id":["10.3389\/fimmu.2020.01147"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2020.01147","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,5]]},"article-number":"1147"}}